A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.

Juan MundisugihHimavan FernandoPeter BerginJames HareDavid KayeAngeline LeetDavid McGiffinAndrew J Taylor

Published in: Progress in transplantation (Aliso Viejo, Calif.) (2019)

The combination of ATG and basiliximab was more effective in preventing acute cellular rejection. In those patients treated with basiliximab, rejection rates were no worse than standard therapy; however, it was only effective when administered within 24 hours.

Keyphrases

liver failure
respiratory failure
aortic dissection
drug induced
oxidative stress
hepatitis b virus
mesenchymal stem cells
cell therapy
acute respiratory distress syndrome